The aim was to test, for the first time, the possible utility of FOXA1 and/or GATA-3 as classifiers for breast cancer recurrence in this high-risk subset of patients, revealing a stratification of ER-negative tumours with different biological behaviours. This evidence concerns the gene FOXA1 and neoplasm.